

5000

Loc PCT

Docket No. JAB-1415

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : CONTRERAS, et. al.

JCS Rec'd PCT 25 MAR 2002

Serial No. : 09/763,011

Art Unit:

1646

Filed : August 16, 1999

Examiner:

For : DRUG TARGETS IN CANDIDA ALBICANS

I hereby certify that this correspondence is being deposited with the
United States Postal Service as first class mail in an envelope addressed
to: Commissioner For Patents, Washington, D.C. 20231 on

March 19, 2002

(Date of Deposit)

Myra H. McCormack

(Name of applicant, assignee, or Registered Representative)



(Signature)

March 19, 2002

(Date of Signature)

Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37
C.F.R. §§1.97-1.98, information relating to the above-identified
application is hereby disclosed. Inclusion of information in
this statement is not to be construed as an admission that this
information is material as that term is defined in 37 C.F.R.
§1.56(b).

Applicant(s) reserve(s) the right to establish the
patentability of the claimed invention over any of the
information provided herewith, and/or to prove that this
information may not be prior art, and/or to prove that this

information may be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

☒ In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under §1.114, no additional fee is required.

☐ In accordance with §1.129(a), this Information Disclosure Statement is being filed in connection with ☐ the first or ☐ second After Final Submission, therefore:

☐ Statement in Accordance with §1.97(e) (attached);
or

☐ Please charge Deposit Account No. 10-0750/ /
the fee of \$180.00 as set forth in §1.17(p).

☐ In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, or an action that otherwise closes prosecution and that it is accompanied by one of:

- ☐ Statement in Accordance with §1.97(e) (attached);
or
☐ Please charge Deposit Account No. 10-0750/ /
the fee of \$180.00 as set forth in §1.17(p).

☐ In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee. Applicant(s) hereby petition(s) for consideration of this Information Disclosure Statement. Included are: Statement in Accordance with §1.97(e) as set forth below and the fee of \$180.00 as set forth in §1.17(p).

☒ Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.

☐ Copies of references listed on the attached Form PTO-1449 are enclosed herewith EXCEPT THAT:

☐ In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.

☐ If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.

☒ There are no listed references which are not in the English language.


☐ The relevance of those listed references which are not in the English language is as follows:

☐ Attached are copies of search report(s) from corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D.


☐ Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D.

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/JAB-1415/MHM. This form is submitted in triplicate.

Respectfully submitted,


Myra H. McCormack
Reg. No. 36,602
Attorney for Applicants

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(732) 524-6932
DATED: March 19, 2002



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

(use as many sheets as necessary)

Sheet 1 of 4

Application Number	09/763,011
Filing Date	February 14, 2001
First Named Inventor	Contreras et al
Group Art Unit	
Examiner Name	
Attorney Docket Number	JAB-1415

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear	T ⁶
		Office ³	Number ⁴	KindCode ⁵				
	1	WO	9511969	A1	RIBOGENE, INC.	05-04-1995		
	2	WO	0009695	A2	JANSSEN PHARMACEUTICA NV	02-24-2000		
	3	WO	9710360	A1	CHIRON CORPORATION	03-20-1997		
	4	WO	9736925	A1	SCRIPTGEN PHARMACEUTICALS, INC.	10-09-1997		
	5	WO	9737230	A1	SCRIPTGEN PHARMACEUTICALS, INC.	10-09-1997		
	6	WO	9636707	A1	UNIVERSITA DELI STUDI DI ROMA "LA SAPIENZA" (IT/IT)	11-21-1996		
	7	EP	0844307	A1	SMITHKLINE BEECHAM CORPORATION	05-27-1998		


Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 4

Application Number	09/763,011
Filing Date	February 14, 2001
First Named Inventor	
Group Art Unit	
Examiner Name	
Attorney Docket Number	JAB-1415

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	8	Altschul, S.F., et. al., Basic local alignment search tool. J. Mol. Biol. 1990 215: 403-410.	
	9	Arndt, G.M., et. al. Gene regulation by antisense RNA in the fission yeast Schizosaccharomyces pombe. Mol. Gen. Genet. 1995 248: 293-300	
	10	Atkins, D., and W.L. Gerlach. Artificial ribozyme and antisense gene expression in Saccharomyces cerevisiae. Antisense Research and Development 1994 4:109-117	
	11	Atkins, D., et. al.,. Antisense Gene Expression in Yeast. Biol. Chem. Hoppe-Seyler. 1994 Vol. 375:721-729	
	12	Atkins, D., et. al., The ade6 Gene of the Fission Yeast as a target for Antisense and Ribozyme RNA-Mediated Suppression. Antisense Research & Development. 1995 5(4):295-305.	
	13	Bairoch, A., and R. Apweiler. The SWISS-PROT protein sequence data bank and its supplement TrEMBL in 1998. Nucleic Acids Res. 1998 Vol. 26:38-42.	
	14	Baudin, A., et.al., A simple and efficient method for direct gene deletion in Saccharomyces cerevisiae. Nucleic Acids Research. 1993 21(14):3329-30.	
	15	Blin, N., and D.W. Stafford. A general method for isolation of high molecular weight DNA from eukaryotes. Nucleic Acids Res. 1976 3:2303-2308.	
	16	Daly, Simona, et al. Isolation and characterization of a gene encoding α -tubulin from Candida albicans. Gene 1997 187:151-158	
	17	Del Rosario, M., et. al., Positive selection system to screen for inhibitors of human immunodeficiency virus-1 transcription. Nature Biotechnology. 1996 14:1592-1596.	
	18	Dujon, B., European Functional Analysis Network (EUROFAN) and the functional analysis of the Saccharomyces cerevisiae genome. Electrophoresis. 1998 19:617-624.	
	19	Fairhead, C., et. al. "Mass-murder" of ORFs from three regions of chromosome XI from Saccharomyces cerevisiae. Gene. 1998 223:33-46.	
	20	Ferbeyre, G., et. al. Cell cycle arrest promotes trans-hammerhead ribozyme action in yeast. Journal of Biological Chemistry. 1996 271(32):19318-23.	
	21	Fleischmann, R.D., et. al. Whole-genome random sequencing and assembly of Haemophilus influenzae Rd. Science. 1995 269: 496-512	
	22	Fonzi, W.A., and M.Y. Irwin. Isogenic strain construction and gene mapping in Candida albicans. Genetics 1993 134:717-728.	
	23	Fraser, C.M., et. al. The minimal gene complement of Mycoplasma genitalium. Science 1995 270:397-403.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

MAR 25 2002

PTO/SB/08A (08-00)

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 4

Application Number	09/763,011
Filing Date	February 14, 2001
First Named Inventor	Contreras et. al.
Group Art Unit	
Examiner Name	
Attorney Docket Number	JAB-1415

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	24	Hahn, S. Guarente L. Yeast HAP2 and HAP3: transcriptional activators in a heteromeric complex. Science 1988 240:317-21	
	25	Heid, C.A., et. al., Real time quantitative PCR. Genome Methods 1996 6:986-994.	
	26	Jayaram, M., et. al., Properties of REP3: a cis-acting locus required for stable propagation of the Saccharomyces cerevisiae plasmid 2 microns circle. Molecular & Cellular Biology. 1985 5(9):2466-75.	
	27	Jeong, S.W., et. al., The yeast transcription terminator for RNA polymerase I is designed to prevent polymerase slippage. Journal of Biological Chemistry. 1996 271(27):16104-10.	
	28	Johnson, F.B., et. al., Molecular Biology of Aging. Cell. 1999 96:291-302.	
	29	Leuker, C.E., et. al., Sequence and promoter regulation of the PCK1 gene encoding phosphoenolpyruvate carboxykinase of the fungal pathogen Candida albicans. Gene. 1997 192(2):235-40.	
	30	Lie, Y.S., and C.J. Petropoulos. Advances in quantitative PCR technology: 5' nuclease assays. Current Opinion in Biotechnology 1998 9:43-48.	
	31	Livak, K.J., et. al., Oligonucleotides with fluorescent dyes at opposite ends provide a quenched probe system useful for detecting PCR product and nucleic acid hybridization. Genome Research. 1995 4(6):357-62.	
	32	Mandart, E. Effects of mutations in the Saccharomyces cerevisiae RNA14 gene on the abundance and polyadenylation of its transcripts. Mol. Gen. Genet. 1998 258:16-25.	
	33	McMahon, S.B., et. al., The novel ATM-related protein TRRAP is an essential cofactor for the c-Myc and E2F oncoproteins. Cell. 1998 94:363-74.	
	34	Murray, J.A.H., et. al., Antagonistic controls regulate copy number of the yeast 2μ plasmid. EMBO J. 1987 6:4205-4212.	
	35	Nasr, F., et. al., YBR1012, an essential gene from S. cerevisiae: construction of an RNA-antisense conditional allele and isolation of a multicopy suppressor. CR Acad. Sci. Paris. 1994 317:607-613	
	36	Nasr, F., et. al., Artificial antisense regulation of YBR1012 (YBR136w) an essential gene from Saccharomyces cerevisiae which is important for progression through G1/S. Mol. Gen. Genet. 1995 249:51-57.	
	37	Nomura, T., et. al., Promoter selectivity of E. coli RNA polymerase: analysis of the promoter system of convergently-transcribed dnaQ-rnh genes. Nucleic Acids Research. 1985 13(21):7647-61.	
	38	Orlando, C., et. al., Developments in quantitative PCR. Clin. Chem. Lab. Med. 1998 36(5):255-269.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4 of 4

Application Number	09/763,011
Filing Date	February 14, 2001
First Named Inventor	Contreras et al
Group Art Unit	
Examiner Name	
Attorney Docket Number	JAB-1415

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	39	Pla, J., et. al., Understanding Candida albicans at the molecular level. Yeast. 1996 12:1677-1702.	
	40	Reeder, R.H. and W.H. Lang. Terminating transcription in eukaryotes: lessons learned from RNA polymerase I. Trends in Biochemical Sciences. 1997 22(12):473-477.	
	41	Reifenberger, E., et. al., Identification of novel HXT genes in Saccharomyces cerevisiae reveals the impact of individual hexose transporters on glycolytic flux. Molecular Microbiology 1995 16 (1) 157-167	
	42	Sandbaken, Mark G., et. al., Protein Synthesis In Yeast, Journal of Biological Chemistry Vol. 265 No. 26, 1990 15838-15844	
	43	Sinclair, D.A., et. al., Extrachromosomal rDNA circles--a cause of aging in yeast. Cell. 1997 91(7):1033-42.	
	44	Smith, V., et. al., Genetic footprinting: A genomic strategy for determining a gene's function given its sequence. Proc. Natl. Acad. Sci. USA 1995 92:6479-6483.	
	45	Stoesser, G., et. al., The EMBL Nucleotide Sequence Database. Nucleic Acids Res. 1998 26(1):8-15.	
	46	Thompson-Jager, S. et. al., 1990 The intron of the yeast actin gene contains the promoter for an antisense RNA. Current Genetics. 17(3):269-73.	
	47	Thompson, J.R., et. al. An improved protocol for the preparation of yeast cells for transformation by electroporation. Yeast. 1998 14:565-571.	
	48	Thrash, C., et. al. Cloning, characterization, and sequence of the yeast DNA topoisomerase I gene. Proc. Natl. Acad. Sci. USA 1985 82:4374-4378.	
	49	Van Duin, et. al. Conserved pattern of antisense overlapping transcription in the homologous human ERCC-1 and yeast RAD10 DNA repair gene regions. Molecular & Cellular Biology. 1989 9(4):1794-8.	
	50	Wach, A., et. al., New heterologous modules for classical or PCR-based gene disruptions in Saccharomyces cerevisiae. Yeast. 1994 10(13):1793-808.	
	51	Wilson, R.B., et. al., Rapid hypothesis testing with Candida albicans through gene disruption with short homology regions. Journal of Bacteriology. 1999 181(6):1868-74.	
	52	Zhu, J., et. al., A method for fast and pure DNA elution from agarose gels by centrifugal filtration. Bio/Technology. 1985 3:1014-1016.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.